Searchable abstracts of presentations at key conferences in endocrinology

ea0022h1.3 | Oral Communications Highlights 1 | ECE2010

ESE Young Investigator Award

Libe Rossella , Horvath Anelia , Fratticci Amato , Vezzosi Delphine , Coste Joel , Guillaud-Bataille Marine , Groussin Lionel , Clauser Eric , Sanson Marie Laure Raffin , Bertagna Xavier , Stratakis Constantine , Bertherat Jerome

Background: Cushing syndrome due to PPNAD is the main endocrine disorder of CNC, an autosomal dominant multiple neoplasia caused by germline inactivating mutations of the subunit type 1A (PRKAR1A) of the protein kinase A (PKA). In addition, germline inactivating mutations in the gene encoding phosphodiesterase 11A (PDE11A) have been identified in patients with PPNAD.Aim of the study: To investigate the role of PDE11A genetic alterati...

ea0020htc3 | Hot topics: Clinical | ECE2009

ESE Young Investigator Award

Assie Guillaume , de Reynies Aurelien , Rickman David , Tissier Frederique , Groussin Lionel , Rene-Corail Fernande , Dousset Bertrand , Bertagna Xavier , Clauser Eric , Bertherat Jerome

Diagnosing malignancy and assessing the prognosis of adrenocortical tumors is challenging. The aim is to identify molecular predictors of malignancy and of survival.Patients and methods: Of 153 unilateral adrenocortical tumors were studied by microarray (n=92) or RT-qPCR (n=148). A 2-gene predictor of malignancy was built using the disease-free survival as the end-point in a training cohort (n=47), then validated in an independent va...

ea0016s14.3 | Basic highlights | ECE2008

Variants of the phosphodiesterase 11A (PDE11A4) gene and genetic predisposition to adrenocortical tumors (ACT)

Libe Rossella , Fratticci Amato , Coste Joel , Groussin Lionel , Horvath Anelia , Rene-Corail Fernande , Bertagna Xavier , Raffin Sanson Marie-Laure , Stratakis Constantine , Bertherat Jerome

Introduction: We have previously identified (using a whole-genome large scale SNP- screening approach) germline inactivating stop codon mutations of the PDE11A4 in patients with Cushing syndrome due to micronodular adrenal hyperplasia. PDE11A4 is a cAMP/cGMP phosphodiesterase.Aim of the study: To investigate the role of PDE11A genetic alterations in a large cohort of ACT.Materials and methods: Leukocyte DNA from 117 adrenocortical ...

ea0073oc9.5 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Reassessment of the diagnostic criteria of insulinoma: A retrospective monocentric cohort study of 72-h fasting trial in 124 patients

Fideline Bonnet , Devingenteuil Clara , Vaczlavik Anna , Bessiene Laura , Laguillier-Morizot Christelle , Assié Guillaume , Helen Mosnier-Pudar , Terris Benoît , Groussin Lionel , Guibourdenche Jean , Bertherat Jerome

IntroductionFasting trial remains the gold standard to confirm the diagnosis of insulinoma, based on low blood glucose level concomitant with inadequate high insulin level. However, diagnostic criteria are not consensual. Glycemia and insulin thresholds differ between the different consensus statements : endogenous hyperinsulism diagnosis relies on a glycemia < 3 mmol/l associated with an insulin level > 3 mUI/l in Endocrine Society guidelines (2009)...

ea0073pep11.5 | Presented ePosters 11: Adrenal and Cardiovascular Endocrinology | ECE2021

Pre-operative hypercortisolism and post-operative adrenal insufficiency in pheochromocytomas: a single center retrospective analysis of 168 patients

Kourti Eleni , Fideline Bonnet , Vaczlavik Anna , Libe Rossella , Bessiene Laura , Guignat Laurence , Sibony Mathilde , Groussin Lionel , Dousset Bertrand , Assié Guillaume , Bertherat Jerome

IntroductionPheochromocytoma might be associated with hypercortisolism and post-operative adrenal insufficiency. The aim of this study is to determine the frequency of cortisol dysregulation before and after pheochromocytoma surgery.MethodsSingle center retrospective study of consecutive pheochromocytoma patients investigated in the Endocrinology department of Cochin Hospital before and after surgery from 200...

ea0081p15 | Adrenal and Cardiovascular Endocrinology | ECE2022

Decreased steroidogenic enzymes activity in benign adrenocortical tumors is more pronounced in bilateral lesions as determined by steroid profiling in HPLC-MSMS during ACTH stimulation test

Fideline Bonnet , Barat Maxime , Vaczlavik Anna , Jouinot Anne , Bouys Lucas , Laguillier-Morizot Christelle , Zientek Corinne , See Catherine , Larger Etienne , Guignat Laurence , Groussin Lionel , Assie Guillaume , Guibourdenche Jean , Nicolis Ioannis , Menet Marie-Claude , Bertherat Jerome

Objective: Large response of steroids precursors, including 17-hydroxyprogesterone and 11-deoxycortisol, to ACTH has been described in adrenocortical tumors, suggesting the existence of intra-tumoral enzymatic deficiencies. This study aimed to compare steroidogenic enzymes activity in unilateral and bilateral benign tumors using serum steroid profiling in HPLC-MS/MS in basal state and after ACTH 1-24 stimulation.Design and Methods: A serum profile of sev...

ea0090oc6.3 | Oral Communications 6: Endocrine-related Cancer | ECE2023

Tumor microenvironment of adrenocortical carcinoma dissected by single-cell RNA-sequencing

Jouinot Anne , Martin Yoann , Foulonneau Thomas , Bendjelal Yanis , Calvet Philip , Violon Florian , Sibony Mathilde , Daniel De Murat , Armignacco Roberta , Perlemoine Karine , Letourneur Franck , Izac Brigitte , Andrieu Muriel , Berthon Annabel , Ragazzon Bruno , Groussin Lionel , Libe Rossella , Bertherat Jerome , Assie Guillaume

Background: Molecular classification is important for diagnosis and prognosis of adrenocortical tumors (ACT). Transcriptome profiles separate benign ACT (“C2” cluster) from carcinomas (ACC) and identify two groups of ACC, “C1A” (“steroid” and “proliferation” signatures) and “C1B” (“immune” signature), of poor and better prognosis respectively. However, these signatures were characterized at the tissue level (“bul...

ea0090rc6.6 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

C-peptide level concomitant with hypoglycemia gives better performances than insulin for the diagnosis of endogenous hyperinsulinism: a monocentric study of 159 fasting trials

Fideline Bonnet , Devin Clara , Thomeret Louis , Laguillier-Morizot Christelle , Leguy Marie-Clemence , Vaczlavik Anna , Bouys Lucas , Zientek Corinne , Bricaire Leopoldine , Bessiene Laura , Guignat Laurence , Libe Rossella , Mosnier-Pudar Helen , Assie Guillaume , Groussin Lionel , Guibourdenche Jean , Bertherat Jerome

Introduction: The gold standard for insulinoma diagnosis is still 72-hours fasting trial with the aim to trigger Whipple’s triad. In this context, biological diagnosis of endogenous hyperinsulinism relies on the occurrence of a hypoglycemia, concomitant with inadequate high insulin and C-peptide levels. However, diagnostic cut-offs are not consensual among the different learned societies (Endocrine Society 2009, NANETS 2010, ENETS 2012). The objective of this wor...

ea0090p369 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the Cranioexe randomized placebo-controlled trial

Gatta-Cherifi Blandine , Mohammedi Kamel , Cariou Tanguy , Poitou-Bernert Christine , Touraine Philippe , Raverot Gerald , Brue Thierry , Chanson Philippe , Illouz Frederic , Solange Grunenwald , Chabre Olivier , Sonnet Emmanuel , Cuny Thomas , Bertherat Jerome , Czernichow Sebastien , Frison Eric , Tabarin Antoine

Background: Hyperphagia leading to craniopharyngioma-related obesity (CRO) is a common and serious sequel of treatments of craniopharyngiomas. The few therapeutic approaches that have been tested until now for the control of eating behaviour and weight have poor efficacy. Glucagon-like peptide-1 (GLP-1) analogues might be an option. Methods: This multicentre, randomised, double-blind superiority trial was conducted in France. Adults with CRO (BMI > 3...

ea0063oc10.3 | Adrenal 2 | ECE2019

Genetic predisposition to Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH): next generation sequencing ARMC5, NR3C1 (glucocorticoid receptor) and PDE11A4 (phosphodiesterase 11) in 389 patients

Vaczlavik Anna , Vaduva Patricia , Bouys Lucas , Neou Mario , Septier Amandine , Heurtier Victor , Libe Rossella , Kroiss Matthias , Borson-Chazot Francoise , Chanson Philippe , Vanthyghem Marie-Christine , Tabarin Antoine , Assie Guillaume , Stratakis Constantine , Fragoso Maria , Ragazzon Bruno , Bertherat Jerome

Introduction: PBMAH is an heterogeneous disease from the clinical, hormonal, and morphological point of view. ARMC5 inactivating mutations have been reported as a cause of PBMAH. PDE11A4 variants have been associated with PBMAH and NR3C1 variants with bilateral adrenal incidentalomas.Aim: To analyse the frequency of ARMC5 pathogenic mutations and PDE11A4 and NR3C1 variants in PBMAH patients.<p cla...